A broad menu of quality assays means more information for doctors
We believe many of the world’s most serious diseases can be overcome by having the right knowledge as soon as possible. At Ortho Clinical Diagnostics, we constantly evaluate our assay portfolio to bring you a broad disease-state menu that meets your testing needs.
Our broad immunoassay menu covers all the major disease states including:
+ Cardiology, Infectious Disease, Oncology
+ Thyroid, Metabolic, Endocrine, Anemia
+ Wide accessible menu onboard at all times
+ Standardized reagents and results across all VITROS® platforms
World-class assays for quality results
VITROS® Troponin I ES Assay
Improved sensitivity delivers more reliable information for patients with acute coronary syndrome. Meets ACC/ESC guideline for acceptable imprecision in a high sensitivity assay (10% CV at 99th percentile).
VITROS® NT-proBNP Assay
Provides confidence to physicians for the differential diagnosis of heart failure, improving patient care. Enables consolidated cardiac testing on one fully random-access system. Adopted in ESC/ACC/AHA practice guidelines.1,2
VITROS® TSH 3rd Generation Assay
Third generation sensitivity means this assay can be used as a front-line screen that enables cost-effective algorithmic testing stratetgies.3,4,5,6 Smaller sample volume minimizes costs and operator intervention.
VITROS® Free T4 Assay
Correlates with Equilibrium Dialysis (ED), considered the “Gold Standard” for free hormone analysis.7,8 Not impacted by serum protein concentrations allowing for better differentiation of non-thyroidal illness.
VITROS® ß-hCG II
Wide dynamic range and equivalent results in serum and plasma minimize dilutions, provide flexibility and improve turnaround time.
VITROS Anti-HCV Assay
A version 3.0 fully automated, random-access diagnostic test for IgG antibody to hepatitis C virus. Provides improved sensitivity. Results in less than 60 minutes, available any time in any order.
For information about the full menu for the VITROS® 3600 Immunodiagnostic System, contact your account manager. Find my account manager
1. Remme WJ, Swedberg K, et al. Guidelines for the diagnosis and
treatment ofchronic heart failure, European Society of Cardiology.
Eur Heart Journal. 2001;22:1527-1560.
2. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline
update for the diagnosis and management of chronic heart failure
in the adult. Circulation. 2005;112:e154-e235.
3. Demers LM, Spencer CA. The National Academy of Clinical
Biochemistry LaboratoryMedicine Practice Guidelines, Published
Guidelines; Laboratory support for thediagnosis and monitoring
of thyroid disease. 2002(13).
thyroidfullversionwithcover.pdf. Accessed on July 18, 2008.
4. Stockigt J. Chapter 6B: Clinical strategies in the testing of thyroid
function. In: Thyroid Disease Manager. 2004.
Accessed on July 18, 2008.
5. Spencer, CA; Thyroid Profiling for the 1990s; Free T4 Estimate
or Sensitive TSH Measurement. J Clin Immunology. 1989;12:82-89.
6. Nicoloff JT, Spencer CA; Clinical Review 12; The use and misuse
of the sensitive thyrotropin assays. J Clin Endocrinol Metab.
7. Christofides ND, Wilkinson E, Stoddart M, Ray DC, Beckett, GJ.
Assessment of serum thyroxine binding capacity-dependent biases
in free thyroxine assays. Clin Chem. 1999;45(4):520-5.
8. Sapin R, Schlienger JL, Gasser F, et al. Intermethod discordant
free thyroxine measurements in bone marrow-transplanted patients.
Clin Chem. 2000;46(3):418-22.